Marco Della Peruta

Marco Della Peruta

Auto-generated profile, based on publicly available information

Marco Della Peruta

Department of Academic Haematology, University College London Cancer Institute, London, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ANAmit C. Nathwani
Amit C. Nathwani
URUlreke M. Reiss
Ulreke M. Reiss
ETEdward G.D. Tuddenham
Edward G.D. Tuddenham
CRCecilia Rosales
Cecilia Rosales
PCPratima Chowdary
Pratima Chowdary
ADAndrew M. Davidoff
Andrew M. Davidoff
In patients with severe hemophilia B, gene therapy that is mediated by a novel self-complementary adeno-associated virus serotype 8 (AAV8) vector has been shown to raise factor IX levels for periods of up to 16 months. We wanted to determine the durability of transgene expression, the vector dose–response relationship, and the level of persistent or late toxicity. We evaluated the stability of transgene expression and long-term safety in 10 patients with severe hemophilia B: 6 patients who had been enrolled in an initial phase 1 dose-escalation trial, with 2 patients each receiving a low, intermediate, or high dose, and 4 additional patients who received the high dose (2×1012 vector genomes per kilogram of body weight). The patients subsequently underwent extensive clinical and laboratory monitoring. A single intravenous infusion of vector in all 10 patients with severe hemophilia B resulted in a dose-dependent increase in circulating factor IX to a level that was 1 to 6% of the normal value over a median period of 3.2 years, with observation ongoing. In the high-dose group, a consistent increase in the factor IX level to a mean (±SD) of 5.1±1.7% was observed in all 6 patients, which resulted in a reduction of more than 90% in both bleeding episodes and the use of prophylactic factor IX concentrate. A transient increase in the mean alanine aminotransferase level to 86 IU per liter (range, 36 to 202) occurred between week 7 and week 10 in 4 of the 6 patients in the high-dose group but resolved over a median of 5 days (range, 2 to 35) after prednisolone treatment. In 10 patients with severe hemophilia B, the infusion of a single dose of AAV8 vector resulted in long-term therapeutic factor IX expression associated with clinical improvement. With a follow-up period of up to 3 years, no late toxic effects from the therapy were reported. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00979238.)

10 January 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EMEdoardo Missiaglia
Edoardo Missiaglia
IDIrene Dalai
Irene Dalai
SBStefano Barbi
Stefano Barbi
SBStefania Beghelli
Stefania Beghelli
MFMassimo Falconi
Massimo Falconi
ASAldo Scarpa
Aldo Scarpa
Purpose: We investigated the global gene expression in a large panel of pancreatic endocrine tumors (PETs) aimed at identifying new potential targets for therapy and biomarkers to predict patient outcome. Patients and Methods: Using a custom microarray, we analyzed 72 primary PETs, seven matched metastases, and 10 normal pancreatic samples. Relevant differentially expressed genes were validated by either quantitative real-time polymerase chain reaction or immunohistochemistry on tissue microarrays. Results: Our data showed that: tuberous sclerosis 2 (TSC2) and phosphatase and tensin homolog (PTEN) were downregulated in most of the primary tumors, and their low expression was significantly associated with shorter disease-free and overall survival; somatostatin receptor 2 (SSTR2) was absent or very low in insulinomas compared with nonfunctioning tumors; and expression of fibroblast growth factor 13 (FGF13) gene was significantly associated with the occurrence of liver metastasis and shorter disease-free survival. TSC2 and PTEN are two key inhibitors of the Akt/mammalian target of rapamycin (mTOR) pathway and the specific inhibition of mTOR with rapamycin or RAD001 inhibited cell proliferation of PET cell lines. Conclusion: Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors. The finding of differential SSTR expression raises the potential for SSTR expression to be evaluated as a marker of response to somatostatin analogs. Finally, we identified FGF13 as a new prognostic marker that predicted poorer outcome in patients who were clinically considered free from disease.

4 May 2005 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
PIETROLUIGI MAURIPIETROLUIGI MAURI
PIETROLUIGI MAURI
ASAldo Scarpa
Aldo Scarpa
ANAnna Chiara Nascimbeni
Anna Chiara Nascimbeni
LBLouise Benazzi
Louise Benazzi
EPEmanuela Parmagnani
Emanuela Parmagnani
Claudio SorioClaudio Sorio
Claudio Sorio

1 January 2016 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
JCJason Coombes
Jason Coombes
SCSteve S. Choi
Steve S. Choi
MSMarzena Swiderska-Syn
Marzena Swiderska-Syn
PMPaul Manka
Paul Manka
DRDanielle T. Reid
Danielle T. Reid
WSWING-KIN SYN
WING-KIN SYN

17 May 2017 in OncoImmunology
Verified
Journal Article
Open access
SGSatyen Harish Gohil
Satyen Harish Gohil
SPSolange R. Paredes-Moscosso
Solange R. Paredes-Moscosso
MHMicaela Harrasser
Micaela Harrasser
MVMarzia Vezzalini
Marzia Vezzalini
ASAldo Scarpa
Aldo Scarpa
MPMarco Della Peruta
Marco Della Peruta
We have developed a humanized bi-specific T-cell engager (BiTE) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell surface antigen present on a range of malignancies and cancer-initiating cells. Focusing initially on pancreatic cancer, we demonstrated that our ROR1 BiTE results in T cell mediated and antigen-specific cytotoxicity against ROR1-expressing pancreatic cancer cell lines in vitro at exceedingly low concentrations (0.1 ng/mL) and low effector to target ratios. Our BiTE prevented engraftment of pancreatic tumor xenografts in murine models and reduced the size of established subcutaneous tumors by at least 3-fold. To validate its wider therapeutic potential, we next demonstrated significant cytotoxicity against ovarian cancer in an in vitro and in vivo setting and T-cell-mediated killing of a range of histologically distinct solid tumor cell lines. Overall, our ROR1 BiTE represents a promising immunotherapy approach, because of its ability to target a broad range of malignancies, many with significant unmet therapeutic needs.

7 October 2010 in The Analyst
Verified
Journal Article
Closed access
PDF file
GBGiuseppe Bellisola
Giuseppe Bellisola
MPMarco Della Peruta
Marco Della Peruta
MVMarzia Vezzalini
Marzia Vezzalini
EMElisabetta Moratti
Elisabetta Moratti
Lisa VaccariLisa Vaccari
Lisa Vaccari
Claudio SorioClaudio Sorio
Claudio Sorio
Aimed at developing accurate, reliable and cost-saving analytical techniques for drugs screening we evaluated the potential of Fourier Transform (FT) InfraRed (IR) microspectroscopy (microFTIR) as a quantitative pre-diagnostic approach for the rapid identification of IR signatures of drugs targeting specific molecular pathways causing Chronic Myeloid Leukemia (CML). To obtain reproducible FTIR absorbance spectra at the necessary spatial resolution we optimized sample preparation and acquisition parameters on a single channel Mercury-Cadmium-Telluride (MCT) detector in the spectral interval of frequencies from 4000 to 800 cm−1. Single K562 cells were illuminated by Synchrotron Radiation (SR) and a number of ∼15 K562 cells spread in monolayer were illuminated by a conventional IR source (Globar), respectively. Combining IR spectral data with the results of complementary biochemical investigations carried out in samples by different analytical methods we identified and cross-validated IR signatures of drugs targeting the oncogenic protein BCR/ABL and its associated abnormal tyrosine kinase activity in K562 cell line. Unsupervised pattern recognition performed by Hierarchical Cluster Analysis (HCA) clustered the spectra of single K562 cells in two distinct groups roughly corresponding to living and to apoptotic cells, respectively. The corresponding IR spectral profiles were assumed to represent drug-resistant and drug-sensitive cells. Significant variations with increasing percentages of apoptotic cells were observed after the treatment of K562 cells with drugs that directly or indirectly target BCR/ABL. In conclusion, we suggest that microFTIR associated with multivariate data analysis may be useful to assess drug compounds in ex vivo cancer cell models and possibly peripheral blast cells from CML patients.